{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:37:11Z","timestamp":1789983431001,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008994","name":"European Society of Contraception and Reproductive Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008994","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011327","name":"State Key Laboratory of Environmental Adaptability for Industrial Products","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.atherosclerosis.2020.12.013","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T05:25:41Z","timestamp":1610947541000},"page":"51-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?"],"prefix":"10.1016","volume":"319","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8793","authenticated-orcid":false,"given":"Dan","family":"Atar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wouter","family":"Jukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9777-4763","authenticated-orcid":false,"given":"Bart","family":"Molemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam R.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6821-1504","authenticated-orcid":false,"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-6922","authenticated-orcid":false,"given":"Cesar","family":"CerezoOlmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6615-8535","authenticated-orcid":false,"given":"James","family":"Underberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.12.013_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2020.12.013_bib2","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"issue":"9753","key":"10.1016\/j.atherosclerosis.2020.12.013_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists Collaboration","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.12.013_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.12.013_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-019-0233-y","article-title":"The myth of 'stable' coronary artery disease","volume":"17","author":"Fox","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(19)31950-6","article-title":"Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options","volume":"394","author":"Ray","year":"2019","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.atherosclerosis.2020.12.013_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr. Pract."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2020.12.013_bib8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.12.013_bib9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/CIRCRESAHA.118.313171","article-title":"Lipid-lowering agents","volume":"124","author":"Hegele","year":"2019","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.12.013_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.recesp.2015.11.016","article-title":"Maximum low-density lipoprotein cholesterol lowering capacity achievable with drug combinations. When 50 plus 20 equals 60","volume":"69","author":"Masana","year":"2016","journal-title":"Rev. Esp. Cardiol."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2020.12.013_bib11","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.12.013_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacl.2013.09.009","article-title":"Therapeutic practice patterns related to statin potency and ezetimibe\/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease","volume":"8","author":"Toth","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2020.12.013_bib13","first-page":"1270","article-title":"Ezetimibe use and LDL-C goal achievement: a retrospective database analysis of patients with clinical atherosclerotic cardiovascular disease or probable heterozygous familial hypercholesterolemia","volume":"23","author":"Menzin","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"20","key":"10.1016\/j.atherosclerosis.2020.12.013_bib14","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.12.013_bib15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2020.12.013_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.12.013_bib17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2019.07.015","article-title":"Effects of alirocumab on cardiovascular events after coronary bypass surgery","volume":"74","author":"Goodman","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib18","first-page":"1","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","author":"Guedeney","year":"2019","journal-title":"Eur. Heart J."},{"issue":"9607","key":"10.1016\/j.atherosclerosis.2020.12.013_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists Collaborators","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2020.12.013_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Cholesterol Treatment Trialists Collaboration","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9841","key":"10.1016\/j.atherosclerosis.2020.12.013_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists Collaborators","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.12.013_bib22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.12.013_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/01.CIR.0000140261.58966.A4","article-title":"Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study","volume":"110","author":"Okazaki","year":"2004","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2020.12.013_bib24","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.12.013_bib25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/M15-2994","article-title":"Proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review","volume":"164","author":"Navarese","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2020.12.013_bib26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2020.12.013_bib27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/clc.23112","article-title":"Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial","volume":"41","author":"Koskinas","year":"2018","journal-title":"Clin. Cardiol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2020.12.013_bib28","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2020.12.013_bib29","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2020.12.013_bib30","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.12.013_bib31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2017","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2020.12.013_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2020.12.013_bib33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/clc.23220","article-title":"Rounding the corner on residual risk: implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease","volume":"42","author":"Baum","year":"2019","journal-title":"Clin. Cardiol."},{"issue":"9567","key":"10.1016\/j.atherosclerosis.2020.12.013_bib34","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.12.013_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib36","series-title":"Vascepa\u00a9 (Icosapent Ethyl)","year":"2019"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.12.013_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2020.12.013_bib38","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2020.12.013_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2019.06.896","article-title":"Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials","volume":"288","author":"Ray","year":"2019","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2020.12.013_bib41","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2020.12.013_bib42","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2020.12.013_bib43","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1373\/clinchem.2007.088013","article-title":"Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease","volume":"53","author":"Dieplinger","year":"2007","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2020.12.013_bib44","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2018.07.001","article-title":"Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease","volume":"276","author":"Sanchez Munoz-Torrero","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib46","series-title":"American College of Cardiology Annual Scientific Session (ACC 2019)","article-title":"Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab - ODYSSEY outcomes","author":"Bittner","year":"2019"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2020.12.013_bib47","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9731","key":"10.1016\/j.atherosclerosis.2020.12.013_bib48","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"issue":"9784","key":"10.1016\/j.atherosclerosis.2020.12.013_bib49","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2020.12.013_bib50","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2020.12.013_bib51","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2020.12.013_bib54","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2020.12.013_bib56","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2020.12.013_bib57","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib58","series-title":"NEXLETOL\u2122 (Bempedoic Acid) Prescribing Information","author":"Us Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib59","series-title":"NEXLIZET\u2122 (Bempedoic Acid and Ezetimibe) Prescribing Information","author":"Us Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib60","series-title":"NILEMDO\u00ae (Bempedoic Acid) Summary of Product Characteristics","author":"European Medicines Agency","year":"2020"},{"key":"10.1016\/j.atherosclerosis.2020.12.013_bib61","series-title":"NUSTENDI\u00ae (Bempedoic Acid\/ezetimibe) Summary of Product Characteristics","author":"European Medicines Agency","year":"2020"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2020.12.013_bib62","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40264-020-00931-6","article-title":"Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies","volume":"43","author":"Cicero","year":"2020","journal-title":"Drug Saf."},{"issue":"15","key":"10.1016\/j.atherosclerosis.2020.12.013_bib63","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2020.12.013_bib64","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2020.12.013_bib65","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc18-1491","article-title":"Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial","volume":"42","author":"Leiter","year":"2019","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2020.12.013_bib66","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2020.12.013_bib67","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/jama.2019.16598","article-title":"Bempedoic acid for lowering LDL cholesterol","volume":"322","author":"Honigberg","year":"2019","journal-title":"JAMA"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020315872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020315872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:25:34Z","timestamp":1762187134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020315872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":67,"alternative-id":["S0021915020315872"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.12.013","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}